Latest filing published 16 Jun 2017 for Celldex Therapeutics, Inc..
No signal scores available.
Based on 11 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This profile gathers the share dealings of Larry Ellberger across 2 companies, led by Celldex Therapeutics, Inc. and Omrix Biopharmaceuticals, Inc. Between 31 May 2007 and 15 June 2017, the trades on record add up to 24 filings.
In open-market terms, that means 11 purchases worth €319k on one side and 1 sale worth €318k on the other. Purchases outweigh sales by €1,038. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 11 share grants and 1 option exercise.
The median purchase comes to €23k. Looking at 11 purchases old enough to measure, the stock rose over the following 90 days in 91% of cases; the median change was +11.2%. Past outcomes like these are no guarantee of what comes next.
The newest entry dates from 16 June 2017: a share grant, in Celldex Therapeutics, Inc. The last purchase on record was published on 26 August 2015, which is 4,077 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 22 declarations